Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin Americ
Description
Market players are focusing on developing effective therapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma which is expected to fuel the market growth over the forecast period. For instance, in November 2020, ADC Therapeutics SA, a late clinical-stage biotechnology company, announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the U.S. Food and Drug Administration (FDA). Lloncastuximab tesirine (Lonca) is developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Moreover, in December 2020, Novartis AG, announced analyses of a 40-month median follow-up from the Phase II JULIET trial, according to which Kymriah, a CAR-T cell therapy, showed safety and efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations and agreements in order to strengthen their market presence which is anticipated to drive the growth of relapsed or refractory diffuse large B-cell lymphoma market. For instance, on June 10, 2020, AbbVie Inc., a publicly traded biopharmaceutical company and Genmab A/S, a biotechnology company, signed a collaboration agreement to develop and commercialize Genmab's early-stage investigational antibody product candidates for cancer. Under this agreement, the companies will commercialize epcoritamab, indicated for B cell malignancies such as diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
Similarly, on June 29, 2020, Karyopharm Therapeutics, Inc., a pharmaceutical company, selected Biologics by McKesson, an independent specialty pharmacy by McKesson Corporation, as a specialty pharmacy provider for XPOVIO, indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)
Key features of the study:
Moreover, in December 2020, Novartis AG, announced analyses of a 40-month median follow-up from the Phase II JULIET trial, according to which Kymriah, a CAR-T cell therapy, showed safety and efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations and agreements in order to strengthen their market presence which is anticipated to drive the growth of relapsed or refractory diffuse large B-cell lymphoma market. For instance, on June 10, 2020, AbbVie Inc., a publicly traded biopharmaceutical company and Genmab A/S, a biotechnology company, signed a collaboration agreement to develop and commercialize Genmab's early-stage investigational antibody product candidates for cancer. Under this agreement, the companies will commercialize epcoritamab, indicated for B cell malignancies such as diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
Similarly, on June 29, 2020, Karyopharm Therapeutics, Inc., a pharmaceutical company, selected Biologics by McKesson, an independent specialty pharmacy by McKesson Corporation, as a specialty pharmacy provider for XPOVIO, indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)
Key features of the study:
- This report provides in-depth analysis of the global relapsed or refractory diffuse large B-cell lymphoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global relapsed or refractory diffuse large B-cell lymphoma market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global relapsed or refractory diffuse large B-cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B-cell Lymphoma market.
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type:
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- MorphoSys US Inc.
- Bristol Myers Squibb
- Karyopharm Therapeutics
- Hoffmann-La Roche AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
Table of Contents
155 Pages
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Trends
- Recent Product Launches/Approvals
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER’s Analysis
- 4. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market – COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
- 5. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, 2020–2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Monjuvi
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- XPOVIO
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- Polivy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- Kymriah
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- Yescarta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Segment Trends
- 6. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Distribution Channel, 2020–2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Mn)
- 7. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Region, 2020–2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020–2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020–2032, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- 8. Competitive Landscape
- Company Profiles
- MorphoSys US Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Karyopharm Therapeutics
- F. Hoffmann-La Roche AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Cellular Biomedicine Group Inc.
- Genmab A/S
- Incyte
- AbbVie Inc.
- Janssen Biotech, Inc.
- Pfizer Inc.
- IMV Inc.
- Overland Pharmaceuticals (CY) Inc.
- ADC Therapeutics SA
- Eagle Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
- Analysts’ Views
- 9. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 26 market data tables and 26 figures on “Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market” – Global forecast to 2032
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
